专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110023142A1 Genetically Modified Rat Models for Cytokine-Cytokine Signaling Pathways 有权
标题翻译：细胞因子 - 细胞因子信号通路的转基因大鼠模型
公开(公告)号：US20110023142A1
公开(公告)日：2011-01-27
申请号：US12842418
申请日：2010-07-23
申请人： Eric M. Ostertag , John Stuart Crawford
发明人： Eric M. Ostertag , John Stuart Crawford
IPC分类号： G01N33/00 , A01K67/027 , C12Q1/02
CPC分类号： C12N15/8509 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0325 , A01K2267/0368
摘要： The present invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in cytokine-cytokine mediated autoimmune and inflammatory disease. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human autoimmune and inflammatory disease and methods of their use. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a cytokine gene such as the Faslg gene, the Fas gene, etc. In one embodiment, the cytokine gene is the Faslg gene. In another embodiment, the cytokine gene is one of several known cytokine genes, such as Fas, IFNγ, TNF-α, IL-2, IL-10, and IL-12. The inactivation of at least one of these cytokine alleles results in an animal with a higher susceptibility to cytokine-cytokine mediated autoimmune and inflammatory disease induction. In one embodiment, the genetically altered animal is a rat of this type and is able to serve as a useful model for cytokine-cytokine mediated autoimmune and inflammatory disease and as a test animal for autoimmune and other studies.
摘要翻译：本发明涉及由于导致细胞因子 - 细胞因子介导的自身免疫和炎性疾病的基因或基因产物的破坏而缺陷的动物细胞，优选哺乳动物，更优选大鼠的工程。另一方面，本发明涉及基因修饰的大鼠，以及这些动物的后裔和祖先，其是人自身免疫和炎性疾病的动物模型及其使用方法。具体地，本发明涉及在细胞因子基因的两个等位基因中的至少一个中的遗传改变的大鼠或培养物中的大鼠细胞，如Faslg基因，Fas基因等。在一个实施方案中，细胞因子基因是Faslg基因。在另一个实施方案中，细胞因子基因是几种已知的细胞因子基因之一，例如Fas，IFNγ，TNF-α，IL-2，IL-10和IL-12。这些细胞因子等位基因中的至少一种的失活导致对细胞因子 - 细胞因子介导的自身免疫和炎性疾病诱导具有较高敏感性的动物。在一个实施方案中，遗传改变的动物是这种类型的大鼠，并且能够用作细胞因子 - 细胞因子介导的自身免疫和炎性疾病的有用模型，并且作为自身免疫和其他研究的测试动物。

2. 发明授权

US08722964B2 Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes 有权
标题翻译：由于种系肿瘤抑制基因破坏而表现出癌症表型的遗传工程或转基因大鼠
公开(公告)号：US08722964B2
公开(公告)日：2014-05-13
申请号：US12766284
申请日：2010-04-23
申请人： Eric M. Ostertag , John Stuart Crawford
发明人： Eric M. Ostertag , John Stuart Crawford
IPC分类号： C12N15/00 , A01K67/027 , C12N15/85
CPC分类号： A01K67/0278 , A01K67/0276 , A01K2217/075 , A01K2217/203 , A01K2227/105 , A01K2267/0331 , C12N15/85 , C12N15/8509 , C12N2015/8527 , C12N2015/8536 , C12N2015/8572 , C12N2800/90
摘要： This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
摘要翻译：本发明涉及由于肿瘤抑制基因或基因产物的破坏而缺乏的动物细胞，优选哺乳动物，更优选的大鼠的工程。另一方面，本发明涉及基因修饰的大鼠，以及这些动物的后裔和祖先，它们是人类癌症的动物模型及其使用方法。

3. 发明授权

US08263752B2 Methods for separating soluble selenoglycoproteins 有权
标题翻译：分离可溶性硒代糖蛋白的方法
公开(公告)号：US08263752B2
公开(公告)日：2012-09-11
申请号：US13051646
申请日：2011-03-18
申请人： Stefan Kwiatkowski , Ronan Power , Clayton Matney , Paiman P. Ghoroghchian , Eric M. Ostertag
发明人： Stefan Kwiatkowski , Ronan Power , Clayton Matney , Paiman P. Ghoroghchian , Eric M. Ostertag
IPC分类号： C07K1/30 , C07K1/36
CPC分类号： C07K14/39 , A61K9/1273 , A61K38/00
摘要： The invention relates to soluble selenium compositions and methods of production, separation and purification thereof. In particular the present invention provides methods of preparing water soluble selenoglycoproteins (e.g., via extracting selenoglycoproteins from selenium enriched yeast), methods of supplementing a selenium deficient composition via admixing water soluble selenoglycoproteins with the selenium deficient composition, compositions comprising the water soluble selenoglycoproteins and methods of administering the same.
摘要翻译：本发明涉及可溶性硒组合物及其生产，分离和纯化方法。特别地，本发明提供了制备水溶性硒代糖蛋白的方法（例如，通过从富硒酵母提取硒代糖蛋白），通过将水溶性硒代糖蛋白与缺硒组合物混合来补充硒缺乏组合物的方法，包含水溶性硒代糖蛋白的组合物和方法的管理。

4. 发明申请

US20130202712A1 Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease 审中-公开
标题翻译：用于治疗或预防免疫炎症的组合物和方法
公开(公告)号：US20130202712A1
公开(公告)日：2013-08-08
申请号：US13582736
申请日：2011-03-02
申请人： Eric M. Ostertag , Paul C. Tumeh , P. Peter Ghoroghchian
发明人： Eric M. Ostertag , Paul C. Tumeh , P. Peter Ghoroghchian
IPC分类号： A61K9/127 , A61K31/7056 , A61K31/327 , A61K31/203 , A61N5/06 , A61K31/05
CPC分类号： A61K9/1273 , A61K9/5146 , A61K31/05 , A61K31/203 , A61K31/327 , A61K31/7056 , A61N5/0613
摘要： The present invention relates to compositions and methods for the treatment of immuno-inflammatory conditions comprising the administration of a polyphenolic phytoalexin compartmentalized in a biocompatible and/or biodegradable polymeric carrier, and to the use of biocompatible and/or biodegradable polymeric carriers comprising resveratrol and block copolymers and these compositions with an additional compartmentalized pharmaceutically active agent.
摘要翻译：本发明涉及用于治疗免疫炎症病症的组合物和方法，其包括施用分隔在生物相容性和/或可生物降解的聚合物载体中的多酚植物抗毒素，以及使用包含白藜芦醇和阻断物的生物相容性和/或可生物降解的聚合物载体共聚物和这些组合物与另外分隔的药物活性剂。

5. 发明申请

US20110145936A1 Genetically Modified Rat Models for Pharmacokinetics 审中-公开
标题翻译：用于药代动力学的转基因大鼠模型
公开(公告)号：US20110145936A1
公开(公告)日：2011-06-16
申请号：US12846891
申请日：2010-07-30
申请人： ERIC M. OSTERTAG , JOHN STUART CRAWFORD
发明人： ERIC M. OSTERTAG , JOHN STUART CRAWFORD
IPC分类号： G01N33/53 , A01K67/027 , G01N33/00
CPC分类号： A01K67/0278 , A01K67/0271 , A01K67/0276 , A01K2207/05 , A01K2207/12 , A01K2207/15 , A01K2207/20 , A01K2217/052 , A01K2217/075 , A01K2217/15 , A01K2227/10 , A01K2227/105 , A01K2267/03 , A01K2267/0306 , C07K14/705 , C12N15/8509 , C12N2800/90 , G01N33/5088 , G01N33/94 , G01N2500/04 , G01N2500/10
摘要： The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the Slc7a11 (NC_005101.2) gene, the Abcb1 (NC_005103.2) gene, etc. The present invention also provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene.
摘要翻译：本发明提供了期望的大鼠或大鼠细胞，其含有预先确定的特异性和期望的改变，使得大鼠或大鼠细胞易于药物转运敏感性或抗药性转运抗性或敏感性。具体地说，本发明涉及一种遗传改变的大鼠或培养物中的大鼠细胞，其在药物转运蛋白基因的两个等位基因中的至少一个中是有缺陷的，例如Slc7a11（NC_005101.2）基因，Abcb1（NC_005103.2））基因等。本发明还提供了期望的大鼠或大鼠细胞，其含有预先确定的特异性和期望的改变，使得大鼠或大鼠细胞易于药物转运敏感性或抗药性转运抗性或敏感性。具体地，本发明涉及在药物转运蛋白基因的两个等位基因的至少一个中缺失的遗传改变的大鼠或培养物中的大鼠细胞。

6. 发明申请

US20110035816A1 Genetically Modified Rat Models for Drug Metabolism 审中-公开
标题翻译：用于药物代谢的转基因大鼠模型
公开(公告)号：US20110035816A1
公开(公告)日：2011-02-10
申请号：US12850921
申请日：2010-08-05
申请人： Eric M. Ostertag , John Stuart Crawford
发明人： Eric M. Ostertag , John Stuart Crawford
IPC分类号： G01N33/68 , A01K67/027 , C12Q1/02
CPC分类号： A01K67/0276 , A01K2207/05 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/03 , C07K14/705 , C12N15/8509 , C12N2800/90 , G01N33/94 , G01N2500/04 , G01N2500/10
摘要： The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to alterations in drug and chemical metabolism by modification of its structure or mechanism. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug metabolism gene such as the Cyp7b1 gene, the Cyp3a4 gene, etc. In another embodiment, the rat cell is a somatic cell. The inactivation of at least one drug metabolism allele results in an animal with a higher susceptibility to altered drug and chemical metabolism. In one embodiment, the genetically altered animal is a rat of this type and is able to serve as a useful model for altered drug and chemical metabolism or toxicology and as a test animal for autoimmune and other studies. The invention additionally pertains to the use of such rats or rat cells, and their progeny in research and medicine. In one embodiment, the invention provides a genetically modified or chimeric rat cell whose genome comprises two chromosomal alleles of a drug metabolism gene wherein at least one of the two alleles contains a mutation, or the progeny of the cell.
摘要翻译：本发明提供了期望的大鼠或大鼠细胞，其包含预定义的特异性和期望的改变，使得大鼠或大鼠细胞易于改变其结构或机制而改变药物和化学代谢。具体地说，本发明涉及在诸如Cyp7b1基因，Cyp3a4基因等药物代谢基因的两个等位基因中的至少一个中缺失的基因改变的大鼠或培养物中的大鼠细胞。在另一个实施方案中，大鼠细胞是体细胞。至少一种药物代谢等位基因的失活导致对改变的药物和化学代谢具有较高敏感性的动物。在一个实施方案中，遗传改变的动物是这种类型的大鼠，并且能够用作改变的药物和化学代谢或毒理学的有用模型，并且作为用于自身免疫和其他研究的测试动物。本发明还涉及这些大鼠或大鼠细胞及其后代在研究和医学中的应用。在一个实施方案中，本发明提供了遗传修饰或嵌合的大鼠细胞，其基因组包含药物代谢基因的两个染色体等位基因，其中两个等位基因中的至少一个含有突变或细胞的后代。

7. 发明授权

US09314005B2 Genetically modified rat models for severe combined immunodeficiency (SCID) 有权
标题翻译：用于严重联合免疫缺陷（SCID）的转基因大鼠模型
公开(公告)号：US09314005B2
公开(公告)日：2016-04-19
申请号：US13391307
申请日：2010-07-01
申请人： Eric M. Ostertag , John Stuart Crawford , Joseph Ruiz
发明人： Eric M. Ostertag , John Stuart Crawford , Joseph Ruiz
IPC分类号： C12N15/00 , A01K67/033 , A01K67/027 , G01N33/00 , C12N9/12 , C12N9/14 , C12N9/22 , C12N15/85 , C12N15/87 , C12N15/90
CPC分类号： A01K67/0276 , A01K2217/054 , A01K2217/056 , A01K2217/15 , A01K2217/20 , A01K2217/206 , A01K2227/105 , A01K2267/0331 , A01K2267/0387 , C12N9/1205 , C12N9/14 , C12N9/22 , C12N15/8509 , C12N15/87 , C12N15/907 , C12N2015/8536
摘要： This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
摘要翻译：本发明涉及由于肿瘤抑制基因或基因产物的破坏而缺乏的动物细胞，优选哺乳动物，更优选的大鼠的工程。另一方面，本发明涉及基因修饰的大鼠，以及这些动物的后裔和祖先，它们是人类癌症的动物模型及其使用方法。

8. 发明申请

US20140201858A1 METHODS FOR SITE-SPECIFIC GENETIC MODIFICATION IN STEM CELLS USING XANTHOMONAS TAL NUCLEASES (XTN) FOR THE CREATION OF MODEL ORGANISMS 审中-公开
标题翻译：使用XANTHOMONAS TAL NUCLEASES（XTN）创建模型有机体的干细胞基因特异性修饰方法
公开(公告)号：US20140201858A1
公开(公告)日：2014-07-17
申请号：US14118544
申请日：2012-05-17
申请人： Eric M. Ostertag , John S. Crawford , J. Keith Joung
发明人： Eric M. Ostertag , John S. Crawford , J. Keith Joung
IPC分类号： C12N15/85
CPC分类号： C12N15/8509 , A01K67/0275 , A01K67/0276 , A01K2217/00 , A01K2227/105 , A01K2227/108
摘要： The invention relates to organisms and compositions comprising one or more stem cells or one or more embryos, wherein the one or more stem cells or one or more embryos comprise one or more of the following mutations: (i) a deletion mutation; (ii) a knockout mutation; and/or (iii) an addition of a heterologous nucleic acid sequence; wherein the one or more mutations of (i), (ii), and/or (iii) are site-specific mutations caused by a Xanthomonas TAL nuclease (XTN). The invention also relates to method of mutating an embryo, iPS cell, stem cell, or more particularly a spermatogonial stem cell by exposing the nucleic acid sequence contained within such embryos or cell with a Xanthomonas TAL nuclease.
摘要翻译：本发明涉及包含一种或多种干细胞或一种或多种胚胎的生物体和组合物，其中所述一种或多种干细胞或一种或多种胚胎包含一个或多个以下突变：（i）缺失突变; （ii）敲除突变; 和/或（iii）异源核酸序列的添加; 其中（i），（ii）和/或（iii）的一个或多个突变是由黄单胞菌TAL核酸酶（XTN）引起的位点特异性突变。本发明还涉及通过用Xanthomonas TAL核酸酶暴露包含在这样的胚胎或细胞内的核酸序列来突变胚胎，iPS细胞，干细胞或更特别是精原干细胞的方法。

9. 发明授权

US08558055B2 Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory disease 有权
标题翻译：包含细胞因子基因破坏并且对细胞因子介导的自身免疫和/或炎性疾病表现出更大易感性的转基因大鼠
公开(公告)号：US08558055B2
公开(公告)日：2013-10-15
申请号：US12842418
申请日：2010-07-23
申请人： Eric M. Ostertag , John Stuart Crawford
发明人： Eric M. Ostertag , John Stuart Crawford
IPC分类号： C12N15/00 , A01K67/033 , A01K67/027 , G01N33/00
CPC分类号： C12N15/8509 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0325 , A01K2267/0368
摘要： The present invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in cytokine-cytokine mediated autoimmune and inflammatory disease. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human autoimmune and inflammatory disease and methods of their use. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a cytokine gene such as the Faslg gene, the Fas gene, etc. In one embodiment, the cytokine gene is the Faslg gene. In another embodiment, the cytokine gene is one of several known cytokine genes, such as Fas, IFNγ, TNF-α, IL-2, IL-10, and IL-12. The inactivation of at least one of these cytokine alleles results in an animal with a higher susceptibility to cytokine-cytokine mediated autoimmune and inflammatory disease induction. In one embodiment, the genetically altered animal is a rat of this type and is able to serve as a useful model for cytokine-cytokine mediated autoimmune and inflammatory disease and as a test animal for autoimmune and other studies.
摘要翻译：本发明涉及由于导致细胞因子 - 细胞因子介导的自身免疫和炎性疾病的基因或基因产物的破坏而缺陷的动物细胞，优选哺乳动物，更优选大鼠的工程。另一方面，本发明涉及基因修饰的大鼠，以及这些动物的后裔和祖先，其是人自身免疫和炎性疾病的动物模型及其使用方法。具体地，本发明涉及在细胞因子基因的两个等位基因中的至少一个中的遗传改变的大鼠或培养物中的大鼠细胞，如Faslg基因，Fas基因等。在一个实施方案中，细胞因子基因是Faslg基因。在另一个实施方案中，细胞因子基因是几种已知的细胞因子基因之一，例如Fas，IFNgamma，TNF-α，IL-2，IL-10和IL-12。这些细胞因子等位基因中的至少一种的失活导致对细胞因子 - 细胞因子介导的自身免疫和炎性疾病诱导具有较高敏感性的动物。在一个实施方案中，遗传改变的动物是这种类型的大鼠，并且能够用作细胞因子 - 细胞因子介导的自身免疫和炎性疾病的有用模型，并且作为自身免疫和其他研究的测试动物。

10. 发明申请

US20120177577A1 Genetically Modified Rat Models for Severe Combined Immunodeficiency (SCID) 有权
标题翻译：重症联合免疫缺陷（SCID）的转基因大鼠模型
公开(公告)号：US20120177577A1
公开(公告)日：2012-07-12
申请号：US13391307
申请日：2010-07-01
申请人： Eric M. Ostertag , John Stuart Crawford , Joseph Ruiz
发明人： Eric M. Ostertag , John Stuart Crawford , Joseph Ruiz
IPC分类号： A61K49/00 , A01K67/027
CPC分类号： A01K67/0276 , A01K2217/054 , A01K2217/056 , A01K2217/15 , A01K2217/20 , A01K2217/206 , A01K2227/105 , A01K2267/0331 , A01K2267/0387 , C12N9/1205 , C12N9/14 , C12N9/22 , C12N15/8509 , C12N15/87 , C12N15/907 , C12N2015/8536
摘要： This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are dencient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
摘要翻译：本发明涉及由于肿瘤抑制基因或基因产物的破坏而无效的动物细胞，优选哺乳动物，更优选的大鼠的工程。另一方面，本发明涉及基因修饰的大鼠，以及这些动物的后裔和祖先，它们是人类癌症的动物模型及其使用方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式